167 related articles for article (PubMed ID: 18090404)
1. First phase I clinical trial of an HIV-1 subtype D gp140 envelope protein vaccine: immune activity induced in all study participants.
Hurwitz JL; Lockey TD; Jones B; Freiden P; Sealy R; Coleman J; Howlett N; Branum K; Slobod KS
AIDS; 2008 Jan; 22(1):149-51. PubMed ID: 18090404
[TBL] [Abstract][Full Text] [Related]
2. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope.
Barnett SW; Srivastava IK; Kan E; Zhou F; Goodsell A; Cristillo AD; Ferrai MG; Weiss DE; Letvin NL; Montefiori D; Pal R; Vajdy M
AIDS; 2008 Jan; 22(3):339-48. PubMed ID: 18195560
[TBL] [Abstract][Full Text] [Related]
3. Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes.
McBurney SP; Young KR; Ross TM
Virology; 2007 Feb; 358(2):334-46. PubMed ID: 17011011
[TBL] [Abstract][Full Text] [Related]
4. Candidate HIV-1 gp140DeltaV2, Gag and Tat vaccines protect against experimental HIV-1/MuLV challenge.
Bråve A; Hinkula J; Cafaro A; Eriksson LE; Srivastava IK; Magnani M; Ensoli B; Barnett SW; Wahren B; Rollman E
Vaccine; 2007 Sep; 25(39-40):6882-90. PubMed ID: 17707956
[TBL] [Abstract][Full Text] [Related]
5. Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap.
Gray GE; Mayer KH; Elizaga ML; Bekker LG; Allen M; Morris L; Montefiori D; De Rosa SC; Sato A; Gu N; Tomaras GD; Tucker T; Barnett SW; Mkhize NN; Shen X; Downing K; Williamson C; Pensiero M; Corey L; Williamson AL
Clin Vaccine Immunol; 2016 Jun; 23(6):496-506. PubMed ID: 27098021
[TBL] [Abstract][Full Text] [Related]
6. Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein.
Wright PF; Mestecky J; McElrath MJ; Keefer MC; Gorse GJ; Goepfert PA; Moldoveanu Z; Schwartz D; Spearman PW; El Habib R; Spring MD; Zhu Y; Smith C; Flores J; Weinhold KJ;
J Infect Dis; 2004 Apr; 189(7):1221-31. PubMed ID: 15031791
[TBL] [Abstract][Full Text] [Related]
7. Induction of HIV-1 subtype B and AE-specific neutralizing antibodies in mice and macaques with DNA prime and recombinant gp140 protein boost regimens.
Center RJ; Wheatley AK; Campbell SM; Gaeguta AJ; Peut V; Alcantara S; Siebentritt C; Kent SJ; Purcell DF
Vaccine; 2009 Nov; 27(47):6605-12. PubMed ID: 19712773
[TBL] [Abstract][Full Text] [Related]
8. Narrowed TCR diversity for immunised mice challenged with recombinant influenza A-HIV Env(311-320) virus.
Cukalac T; Moffat JM; Venturi V; Davenport MP; Doherty PC; Turner SJ; Stambas J
Vaccine; 2009 Nov; 27(48):6755-61. PubMed ID: 19744584
[TBL] [Abstract][Full Text] [Related]
9. The therapeutic phase I trial of the recombinant native HIV-1 Tat protein.
Ensoli B; Fiorelli V; Ensoli F; Lazzarin A; Visintini R; Narciso P; Di Carlo A; Monini P; Magnani M; Garaci E
AIDS; 2008 Oct; 22(16):2207-9. PubMed ID: 18832884
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults.
Nitayaphan S; Pitisuttithum P; Karnasuta C; Eamsila C; de Souza M; Morgan P; Polonis V; Benenson M; VanCott T; Ratto-Kim S; Kim J; Thapinta D; Garner R; Bussaratid V; Singharaj P; el-Habib R; Gurunathan S; Heyward W; Birx D; McNeil J; Brown AE;
J Infect Dis; 2004 Aug; 190(4):702-6. PubMed ID: 15272397
[TBL] [Abstract][Full Text] [Related]
11. [A novel immunization strategy to induce strong humoral responses against HIV-1 using combined DNA, recombinant vaccinia virus and protein vaccines].
Liu C; Wang SH; Ren L; Hao YL; Zhang QC; Liu Y
Bing Du Xue Bao; 2014 Nov; 30(6):645-51. PubMed ID: 25868279
[TBL] [Abstract][Full Text] [Related]
12. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.
Pitisuttithum P; Gilbert P; Gurwith M; Heyward W; Martin M; van Griensven F; Hu D; Tappero JW; Choopanya K;
J Infect Dis; 2006 Dec; 194(12):1661-71. PubMed ID: 17109337
[TBL] [Abstract][Full Text] [Related]
13. Feeding of mice with Arabidopsis thaliana expressing the HIV-1 subtype C p24 antigen gives rise to systemic immune responses.
Lindh I; Kalbina I; Thulin S; Scherbak N; Sävenstrand H; Bråve A; Hinkula J; Strid A; Andersson S
APMIS; 2008 Nov; 116(11):985-94. PubMed ID: 19132995
[TBL] [Abstract][Full Text] [Related]
14. Maternal immune status influences HIV-specific immune responses in pups after DNA prime protein boost using mucosal adjuvant.
Bråve A; Johansen K; Palma P; Benthin R; Hinkula J
Vaccine; 2008 Nov; 26(47):5957-66. PubMed ID: 18801400
[TBL] [Abstract][Full Text] [Related]
15. Inclusion of the viral anti-apoptotic molecule M11L in DNA vaccine vectors enhances HIV Env-specific T cell-mediated immunity.
Su J; Willert C; Comanita L; Peters A; Gilbert PA; Strathdee C; O'Connell PJ; McFadden GD; Dekaban GA
Virology; 2008 May; 375(1):48-58. PubMed ID: 18291435
[TBL] [Abstract][Full Text] [Related]
16. Support for the RV144 HIV vaccine trial.
Belshe R; Franchini G; Girard MP; Gotch F; Kaleebu P; Marthas ML; McChesney MB; McCullough R; Mhalu F; Salmon-Ceron D; Sekaly RP; van Rompay K; Verrier B; Wahren B; Weissenbacher M
Science; 2004 Jul; 305(5681):177-80; author reply 177-80. PubMed ID: 15247455
[No Abstract] [Full Text] [Related]
17. Vaccine-induced HIV seropositivity: a problem on the rise.
Van Braeckel E; Koutsoukos M; Bourguignon P; Clement F; McNally L; Leroux-Roels G
J Clin Virol; 2011 Apr; 50(4):334-7. PubMed ID: 21300566
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of a candidate vaccine based on recombinant HIV-1 gp160 (MN/LAI) administered by the mucosal route to HIV-seronegative volunteers: the ANRS VAC14 study.
Pialoux G; Hocini H; Pérusat S; Silberman B; Salmon-Ceron D; Slama L; Journot V; Mathieu E; Gaillard C; Petitprez K; Launay O; Chêne G;
Vaccine; 2008 May; 26(21):2657-66. PubMed ID: 18068876
[TBL] [Abstract][Full Text] [Related]
19. Enhanced induction of intestinal cellular immunity by oral priming with enteric adenovirus 41 vectors.
Ko SY; Cheng C; Kong WP; Wang L; Kanekiyo M; Einfeld D; King CR; Gall JG; Nabel GJ
J Virol; 2009 Jan; 83(2):748-56. PubMed ID: 18987146
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. Clin Exp Immun 1994;98:178-84.
DePalma L
Pediatr AIDS HIV Infect; 1995 Apr; 6(2):97-8. PubMed ID: 11361387
[No Abstract] [Full Text] [Related]
[Next] [New Search]
